Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis

Abstract Background Each year 25 000–32 000 children develop rifampicin- or multidrug-resistant tuberculosis (RR/MDR-TB), and many more require preventive treatment. Levofloxacin is a key component of RR/MDR-TB treatment and prevention, but the existing pharmacokinetic data in children have not yet...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Clinical infectious diseases Ročník 78; číslo 3; s. 756 - 764
Hlavní autori:	White, Yasmine N, Solans, Belen P, Denti, Paolo, van der Laan, Louvina E, Schaaf, H Simon, Vonasek, Bryan, Malik, Amyn A, Draper, Heather R, Hussain, Hamidah, Hesseling, Anneke C, Garcia-Prats, Anthony J, Savic, Radojka M
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	US Oxford University Press 20.03.2024
Predmet:	Adult Antitubercular Agents Child Humans Infant Infant, Newborn Levofloxacin Rifampin - pharmacokinetics Rifampin - therapeutic use Tablets - therapeutic use Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - prevention & control pharmacokinetics levofloxacin drug-resistant tuberculosis pediatrics
ISSN:	1058-4838, 1537-6591, 1537-6591
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!